Exercise may fight fatty liver in seniors, new study hopes to prove
NCT ID NCT07467512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a 12-week exercise program (strength and aerobic training twice a week) affects liver fat, inflammation, and scarring in people with metabolic fatty liver disease. It compares results between older adults (70+) and middle-aged adults (40-60), as well as between those with mild and more advanced liver disease. The goal is to see if exercise helps liver health regardless of age or disease severity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Middle-aged adults (40 to 60 years old) and older adults (aged 70 years or older) * People diagnosed with Metabolic Disfunction-Associated Steatotic Liver Disease (MASLD); defined as the presence of hepatic steatosis (≥5% fat content) in conjunction with at least one cardiometabolic risk factor (overweight or obesity, dysglycaemia or Type II diabetes, elevated plasma triglycerides, reduced HDL-cholesterol or high blood preassure) with no other discernable cause. * People diagnosed with at-risk Metabolic Disfunction-Associated SteatoHepatitis (MASH) according to the following criteria: I) a positive liver biopsy (NAS score ≥ 4 points (with at least one point in each of the components of the score: steatosis, lobular inflammation and ballooning, AND significant (F2) or advanced (F3) fibrosis), or II) a FAST score \>0.65. Exclusion Criteria: * Descompensated cirrhosis or end-stage liver disease. * Other causes of liver disease, such as alcohol abuse or drug-induced, virus-related, or hereditary disease. * History of a major adverse cardiovascular event, clinically significant kidney, endocrine, or neurological disease, bariatric surgery, HIV/AIDS, known inflammatory and/or rheumatologic disease, cancer, or other medical condition in which exercise is absolute contraindicated. * Recent or planned major surgery, as well as anticancer therapies. * Participating in a weight loss, a weight-management program or a supervised exercise program (more than 30 minutes three times per week, or 45 minutes twice a week, moderate/vigorous intensity). * Body weight instability. Participants must have maintained the body weight registered at screening visit (tolerance: 5%) for more than 3 months. * Regular use of medication or compounds that may affect study outcomes based on research staff criteria. * Pregnancy and lactation or planned pregnancy (within the study period). * Frequent travel over time zones during the study period. * Fear of needles and claustrophobia to magnetic resonance imaging (MRI). * Low physical function (ie, ambulation dependency) * Being unable to understand and to accept the instructions or the study objectives and protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Liver fibrosis/NASH are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital General Universitario Gregorio Marañon
Madrid, 28007, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a liver risk score predict early death from routine checkups?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test
- Can a new injection tackle obesity, diabetes, and liver disease?
- A simple scan and blood test could catch silent liver scarring before It's too late
- A simple body scan may spot fatty liver disease without needles
- Could a once-daily pill help children with fatty liver disease?